Company: INTS
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001567264-25-000010
Chunk: 37

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 37
---
321 50 Net cash provided by financing activities2,900 20,472 Net (decrease) increase in cash and cash equivalents(5,966)7,244 Cash and cash equivalents at beginning of period8,556 1,312 Cash and cash equivalents at end of period$2,590 $8,556 Supplemental disclosure of non-cash financing activities:Right-of-use lease asset and operating lease liability$- $155 Convertible notes issued in exchange for services$- 13 Conversion of convertible notes and accrued interest into common stock$- $4,737 Warrants issued in relation to issuance of convertible notes$- $159 Warrants issued to underwriter in connection with stock issuance$1,068 $1,170 Preferred stock deemed dividend$- $1,324 

The accompanying notes are an integral part of these financial statements.

F-6

INTENSITY THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

Note 1.    Description of Business

Intensity Therapeutics, Inc. (“the Company”) is a biotechnology company whose treatment approach addresses both the regional and systemic nature of a patient’s cancer. The Company’s DfuseRxSM technology platform has identified a lead drug, INT230-6.  The Company is based in Connecticut and was incorporated in Delaware in December 2012.  As a result of its initial public offering (the “IPO”) that priced on June 29, 2023, the Company began trading on the Nasdaq Capital Market under the symbol “INTS” on June 30, 2023. The IPO closed on July 5, 2023 at the IPO price of $5.00 per share, at which time the Company issued 3,900,000 shares of our common stock for gross proceeds of $19.5 million.  After deducting offering expenses of $2.0 million, the Company received net proceeds received of $17.5 million. On July 7, 2023, the Company sold the full over-allotment shares at the IPO price of $5.00 per share, resulting in the issuance of 585,000 shares of our common stock for gross proceeds of $2.9 million. After deducting offering expenses of $0.2 million, the Company received an additional $2.7 million in net cash proceeds. The Company has used the net proceeds from the IPO